KR880701246A - 재조합 페포 계면활성제 단백질 - Google Patents

재조합 페포 계면활성제 단백질

Info

Publication number
KR880701246A
KR880701246A KR1019870701256A KR870701256A KR880701246A KR 880701246 A KR880701246 A KR 880701246A KR 1019870701256 A KR1019870701256 A KR 1019870701256A KR 870701256 A KR870701256 A KR 870701256A KR 880701246 A KR880701246 A KR 880701246A
Authority
KR
South Korea
Prior art keywords
protein
dna
asp
mixture
carbohydrate
Prior art date
Application number
KR1019870701256A
Other languages
English (en)
Inventor
더블유.쉴링 제임스
티.화이트 로버트
코오델 바바라
제이.벤슨 브래드리
Original Assignee
원본미기재
캘리포니아 바이오테크놀로지 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 캘리포니아 바이오테크놀로지 인코오퍼레이티드 filed Critical 원본미기재
Publication of KR880701246A publication Critical patent/KR880701246A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

재조합 페포 계면활성제 단백질
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 제 위치에서 정상적으로 수반되는 단백질 유리 페포계면활성제 단백질(ASP)에 있어서, 사람 SP-18 DNA와 사람 SP-5 DNA및 그의 프로세스된 형태를 포함하는데 의해 코드되는 단백질로 이루어지는 군으로부터 선택되는 페포계면활성제 단백질(ASP)
  2. 제1항에 있어서, 제2도, 제3도, 제5도 또는 제6도에 도시된 DNA 또는 그와 실질적으로 동등한 DNA에 의해 코드되는 것을 특징으로 하는 단백질.
  3. 제1항의 단백질을 코드하는 재조합 DNA서열에 있어서, DNA는 제1항의 단백질을 정상적으로 수반하는 단백질을 코드하는 DNA가 유리된 것을 특징으로 하는 재조합 DNA서열.
  4. 제3항에 있어서, 적당한 재조합 숙주세포에서 상기 서열의 발현에 효과적인 제어 서열에 활발하게 연결되는 것을특징으로 하는 DNA.
  5. 제3항의 DNA또는 제4항의 발현시스템으로 형질전환되는 제조합숙주세포.
  6. 제5항의 세포를 배양하는 것을 포함하는 ASP제조방법.
  7. 제6항의 방법에 의해 제조된 재조합 ASP.
  8. 32K ASP 단백질의 정제 방법에 있어서, (a) 32K 단백질이 탄수화물 결합 지지에 흡수되어 있는 조건하에서 혼합물과 탄수화물 결합지지의 접촉; 및 (b) 단백질이 결합되지 않은 조건하에서 32K 단백질의 용리에 의해 탄수화물 결합 지지를 사용하여 상기 32K단백질을 함유하는 혼합물에 탄수화물 친화성 크로마토그래피를 수행하는 것으로 이루어지는 32K ASP 단백질의 정제방법.
  9. 제8항에 있어서, 탄수화물 친화성은 만노스 잔기에 의해 공급되고, 32K단백질의 지지에의 결합은 칼슘이온의 존재하에 수행되며 상기 32K단백질의 용리는 칼슘이온의 존재하에 수행되며 상기 32K 단백질의 용리는 칼슘이온 농도를 감소시키는 조건하에 있는 것을 특징으로 하는 방법.
  10. 제8항의 방법에 의하여 정제되는 ASP 단백질.
  11. 인지질 제제와, 가장 적당하게는 약제학적 수용가능한 부형제와의 혼합물 형태로 제1항 또는 제7항 또는 제10항의 단백질을 포함하는 조성물로서 포유류에서 호흡을 위한 (RDS)치료에 효과적인 약제학적 조성물.
  12. 인지질 제제와, 가장 적당하게는 약제학적 수용가능한 부형제와의 혼합물 형태의 32K ASP 단백질의 효과적인 양과의 혼합물 형태로 제1항 또는 제7항 또는 제10항의 단백질을 포함하는 조성물로서 포유류에서 RDS치료에 효과적인 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870701256A 1986-04-30 1987-04-30 재조합 페포 계면활성제 단백질 KR880701246A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/857,715 US4933280A (en) 1984-12-11 1986-04-30 Recombinant DNA sequence encoding Alveolar Surfactant Protein
US857715 1986-04-30
PCT/US1987/000978 WO1987006588A1 (en) 1986-04-30 1987-04-30 Recombinant alveolar surfactant protein

Publications (1)

Publication Number Publication Date
KR880701246A true KR880701246A (ko) 1988-07-26

Family

ID=25326586

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870701256A KR880701246A (ko) 1986-04-30 1987-04-30 재조합 페포 계면활성제 단백질

Country Status (14)

Country Link
US (1) US4933280A (ko)
EP (1) EP0251449B1 (ko)
JP (3) JPH0813839B2 (ko)
KR (1) KR880701246A (ko)
AT (1) ATE118035T1 (ko)
AU (1) AU591566B2 (ko)
CA (1) CA1340611C (ko)
DE (1) DE3751033T2 (ko)
DK (1) DK173173B1 (ko)
ES (1) ES2072850T3 (ko)
GR (1) GR3015913T3 (ko)
HK (1) HK1005887A1 (ko)
IL (1) IL82364A (ko)
WO (1) WO1987006588A1 (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3761394A (en) * 1969-12-31 1973-09-25 Texaco Inc Catalytic cracking of naphtha
US5840527A (en) * 1984-12-11 1998-11-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Recombinant alveolar surfactant protein
EP0240550A4 (en) * 1985-09-26 1989-09-19 Genetics Inst LUNG SURFACE ACTIVE PROTEINS.
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
JPH01501282A (ja) * 1986-12-08 1989-05-11 ホイツトセツト，ジエフリー　エイ． 肺胞疎水性界面活性物質関連タンパク質
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
JPH04501204A (ja) * 1988-08-11 1992-03-05 サイオス　ノバ　インコーポレイテッド 異種タンパク発現を安定させる方法およびそれに使用するベクター
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
EP0458167B1 (en) * 1990-05-21 1997-04-23 Abbott Laboratories Fatty acid-pulmonary surfactant conjugates
GB9120005D0 (en) * 1991-09-19 1991-11-06 Wellcome Found Method of administering phospholipid dispersions
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
DE4418936A1 (de) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
US6031075A (en) * 1996-02-05 2000-02-29 Children's Hospital Medical Center Mature alveolar SP-B and a process for producing the same
EP1216052A1 (en) 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
WO2003033014A2 (de) 2001-10-11 2003-04-24 Altana Pharma Ag Neue verwendung von lungensurfactant
ES2339954T3 (es) 2004-08-06 2010-05-27 Nycomed Gmbh Composicion que comprende un agente tensioactivo pulmonar y un peptido derivado de tnf.
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
CA2744940A1 (en) 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4312860A (en) * 1980-10-24 1982-01-26 Regents Of The University Of California Lung surfactant compositions
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4562003A (en) * 1984-10-26 1985-12-31 California Biotechnology, Inc. Monoclonal antibodies against alveolar surfactant protein
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
JPS63503222A (ja) * 1986-05-06 1988-11-24 サイオス　ノバ　インコーポレイテッド 肺の疎水性界面活性物質に結合した分子量６，０００ダルトンのタンパク質及びその多量体
JPH01501282A (ja) * 1986-12-08 1989-05-11 ホイツトセツト，ジエフリー　エイ． 肺胞疎水性界面活性物質関連タンパク質

Also Published As

Publication number Publication date
AU591566B2 (en) 1989-12-07
JP2584962B2 (ja) 1997-02-26
WO1987006588A1 (en) 1987-11-05
ATE118035T1 (de) 1995-02-15
EP0251449B1 (en) 1995-02-01
JPH09117290A (ja) 1997-05-06
ES2072850T3 (es) 1995-08-01
JPH08188598A (ja) 1996-07-23
HK1005887A1 (en) 1999-01-29
EP0251449A3 (en) 1989-04-19
JPH0813839B2 (ja) 1996-02-14
DK151792A (da) 1992-12-17
DE3751033D1 (de) 1995-03-16
US4933280A (en) 1990-06-12
GR3015913T3 (en) 1995-07-31
IL82364A0 (en) 1987-10-30
AU7480287A (en) 1987-11-24
EP0251449A2 (en) 1988-01-07
JP2766806B2 (ja) 1998-06-18
IL82364A (en) 1993-08-18
CA1340611C (en) 1999-06-29
JPH01500350A (ja) 1989-02-09
DE3751033T2 (de) 1995-08-10
DK173173B1 (da) 2000-02-28

Similar Documents

Publication Publication Date Title
KR880701246A (ko) 재조합 페포 계면활성제 단백질
ES2070919T5 (es) Separacion cromatografica de las proteinas del plasma, principalmente del factor viii, del factor de willebrand de la fibronectina y del fibrinogeno.
EP0197901B1 (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
Ikeda et al. Human transforming growth factor type. beta. 2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization
Termine et al. Properties of dissociatively extracted fetal tooth matrix proteins. II. Separation and purification of fetal bovine dentin phosphoprotein.
GB2181138B (en) Recombinant alveolar surfactant protein
ATE192486T1 (de) Chondroitinase, herstellungsverfahren und pharmazeutische zusammensetzung
Lönnroth et al. Purification and characterization of the antisecretory factor: a protein in the central nervous system and in the gut which inhibits intestinal hypersecretion induced by cholera toxin
HUT43188A (en) Monoclonic antibodies and antigenes for treatment of human, having not-small celts carcinoma of lungs
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
KR880003975A (ko) 항응고성 및 항전이성을 갖는 단백질
Stathakis et al. Human fibrinogen heterogeneities. Preparation and characterization of γ and γ′ chains
Lazarovici et al. Affinity chromatographic purification and characterization of two iodinated tetanus toxin fractions exhibiting different binding properties
Hervé et al. Two-step chromatographic purification of human plasma α1-acid glycoprotein Its application to the purification of rare phenotype samples of the protein and their study by chromatography on immobilized metal chelate affinity adsorbent
Araujo et al. Potentiation of bradykinin action on smooth muscle by a scorpion venom extract
KR100371976B1 (ko) 혈장헤파린결합단백질-70
Robinson [13] Purification of tetanus toxin and its major peptides
Puschmann et al. Partial purification procedure for human urinary erythropoietin by preparative isotachophoresis
TAO et al. Isolation and characterization of human urinary colony-stimulating factor
Champagne et al. The Core Histones from the Slime Mold Physarum polycephalum: Isolation and Characterization
Maeda Comparative studies of bovine serum transferrins
Dukovich The Purification and Biochemical Characterization of Natural and Recombinant Interleukin 1
DK318086A (da) Praeparat til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadant praeparat
JPH0867697A (ja) 骨吸収抑制蛋白性物質

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid